{
  "id": 8416840,
  "title": "Harmony Biosciences CMO sells $1.65m in shares",
  "url": "https://urgent.news/2026/09/19/harmony-biosciences-cmo-sells-1-65m-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-19T08:15:57.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/harmony-biosciences-cmo-sells-165m-in-shares-93CH-4908064"
  },
  "original_language": "en",
  "account": null,
  "summary": "Harmony Biosciences Holdings Inc. (HRMY) reported that its Chief Medical Officer, Budur Kumar, sold approximately $1.65 million worth of the company's common stock over three consecutive days in early September 2026. The sales were executed pursuant to a Rule 10b5-1 trading plan, which is designed to avoid accusations of insider trading. The transactions occurred as the stock was trading near its 52-week high of $43.49, following a 51% return over the past six months. The stock remains undervalued according to InvestingPro analysis, with a P/E ratio of 13.96. Additionally, Kumar acquired an equivalent amount of shares through the exercise of stock options, bringing his direct holdings to 13,115 shares. Harmony Biosciences recently reported strong earnings for the second quarter of 2026, surpassing analyst expectations with adjusted earnings per share of $1.28 and record quarterly net sales of $261.3 million. The company reaffirmed its full-year revenue guidance and highlighted progress in its BP-205 orexin-2 program.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}